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Background: IL-21 has been shown to play an important role in autoimmune diseases. ATR-107 is an antibody
which directly targets the IL-21 receptor (IL-21R). To aid the clinical development of ATR-107, there is a need for
understanding the mechanism of action (MOA) of this antibody when assessing target engagement in human
subjects.
Methods: To determine ATR-107 biological activity and potency in human blood, its inhibitory function against
IL-21 induced STAT3 phosphorylation in human peripheral T and B cells was measured.
Results: The data show that IL-21 induces STAT3 phosphorylation in a concentration-dependent manner,
consistent with its migration to the nuclear. Using a flow cytometry based functional whole blood assay, ATR-107 is
demonstrated to be a potent IL-21 pathway inhibitor. It competes with IL-21 for receptor binding in a competitive
manner, but once it binds to the receptor it behaves like a non-competitive inhibitor, most probably due to the
long observed koff. The concentration-dependent inhibition observed with ATR-107 correlates inversely with the
levels of receptor occupancy, both in ex vivo whole blood assays and directly in human blood when ATR-107 was
given to healthy volunteers.
Conclusions: IL-21 induced phosphorylation of STAT3 in T and B cells can be used as a biomarker to evaluate the
target engagement of ATR-107 in human whole blood. The antibody behaves like a potent non-competitive
inhibitor blocking IL-21 induced STAT3 phosphorylation for a long period of time. These results may help with the
translation of preclinical information and dose selection towards ATR-107 clinical efficacy.
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Interleukin-21 (IL-21) is a recently discovered type I
cytokine that modulates the proliferation and function
of various cell types, including T cells, B cells and NK
cells [1]. It also contributes to the development of the
Th17 cell lineage [2].
IL-21 signals through a heterodimeric receptor com-
plex consisting of a shared common gamma chain (γc),
and a high affinity IL-21R alpha chain [3]. IL-21 is
mainly produced by activated CD4+ T cells and by natu-
ral killer T (NKT) cells [4]. The IL-21 receptor however,* Correspondence: ming.zhu1@pfizer.com
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reproduction in any medium, provided the oris expressed in most lymphoid, hematopoietic cells, fi-
broblasts, keratinocytes and intestinal epithelial cells [5].
Once IL-21 binds to its receptor, it activates JAK1 and
JAK3 tyrosine kinases, which in turn phosphorylate
STAT1, STAT3 and STAT5 and initiate the transcription
of regulated genes [6,7]. IL-21 modulates adaptive im-
mune responses by its affect on broad range of immune
cells, including T, B and NK cells [3]. Preclinical data
has revealed the importance of this cytokine in several
autoimmune diseases. For example, in vivo data show
that blockade of IL-21 signaling using an IL-21 receptor
Fc fusion protein (IL-21R Fc) decreases the disease se-
verity in several murine models including collagen-
induced arthritis [8], the MRL-Faslpr lupus model [9]
and the diabetic NOD model [10]. The shared mecha-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pathophysiological role of IL-21 effects on cytokine and
autoantibody production.
The use of biomarkers in drug development is very
important in understanding the mechanism of action,
dose selection and patient stratification. Since STAT3 is
a direct downstream signal of IL-21R activation, and it
plays a critical role in regulating immune responses
[3,4,11-13], we sought to use STAT3 phosphorylation as
a new pharmacodynamic biomarker to understand the
mechanism of action of ATR-107.
In order to block the IL-21 signaling pathway, a high af-
finity humanized antibody was developed to directly target
both human (KD: 2.02 nM) and mouse (KD: 16.72 nM)
IL-21R [14]. Previous studies showed that the antibody
ATR-107 significantly reduces blood anti-dsDNA antibody
level and kidney IgG deposits in the MRL-Faslpr mouse
model of lupus [14]. Its pharmacokinetics and phar-
macodynamic (PD) activity has also been evaluated in
cynomolgus monkeys. Following a single iv dose of
10 mg/kg, the serum half-life (t1/2) was reported to be
approximately 10 days [15]. Interestingly, in these animals,
the PD effect lasted much longer, between 5 and 13 weeks,
when measured by the IL-21 induced IL-2Rα gene expres-
sion [15,16]. The apparent disconnection between phar-
macokinetic and pharmacodynamic of the antibody led us
to investigate its mechanism of action and pharmaco-
logical efficacy in the human system. Thus, a series of ex-
periments were carried out to determine the effects of
ATR-107 on IL-21 induced STAT3 phosphorylation in hu-
man peripheral blood T and B cells. This assay was then
used clinically to evaluate the pharmacodynamic effect of
this drug in healthy volunteers.
Material and methods
Reagents
Recombinant human IL-21 (IL-21), ATR-107, human
IgG triple mutant (IgG1 TM) were prepared by the
Biotherapeutic Technologies Department (Cambridge,
MA) at Pfizer.
Blood was drawn from 14 female and 13 male healthy
volunteers (age 24–61 years) into heparinized collection
tubes in accordance with Pfizer protocol (protocol #:
GOHW RDP-01) approved by the Shulman Institutional
Review Board.
T cell purification
CD4+ T cells from healthy donor peripheral blood were
isolated using RosetteSepW Human CD4+ T Cell Enrich-
ment Cocktail (cat#: 15062) from STEMCELL Tech-
nologies Inc. (Vancouver, Canada), according to the
manufacturer’s instruction. Briefly, RosetteSepW Human
CD4+ T Cell Enrichment Cocktail was added to the blood
at concentration of 50 μL/mL blood and incubated for20 minutes at room temperature. Then the samples were
diluted with an equal volume of PBS + 2% FBS and layered
on top of Ficoll-Paque™ PREMIUM density medium
(Piscataway, NJ). After centrifugation at room temperature
for 20 minutes at 1200 x g, cells at the plasma-Ficoll inter-
face were harvested and washed twice with PBS + 2% FBS.
Cells were counted using Cellometer auto T4 cell counter
(Nexcelom Bioscience, Lawrence, MA).
T cell stimulation
T cells were resuspended in PBS + 2% FBS and aliquoted
into 96 well plates at 1x106 cells/100 μl/well. ATR-107 at
various concentrations was added for 30 minutes before
IL-21 stimulation. 10 ng/ml IL-21 was used and the
stimulation was stopped 15 minutes later by adding 3X
loading buffer (Cell Signaling Technology, Inc., Danvers,
MA) plus proteinase inhibitor and phosphatase inhibitor
cocktail (Sigma-Aldrich Corp. St. Louis, MO). Samples
were then transferred to 1.5 ml Eppendorf tubes and
kept on ice. Fifteen seconds of sonication was used to
shear the DNA and reduce viscosity of the samples.
Western blot
Sonicated samples were heated at 95°C to denature the
proteins, followed by a quick spin in a desktop centri-
fuge. 30 μl of the samples were then loaded and proteins
were separated using a 10% SDS-PAGE Tris-glycine gel
(Invitrogen, Grand Island, NY). Transfer was done with
the iBlotW Gel Transfer system (Invitrogen) onto a nitro-
cellulose membrane. Blocking was done with PBS + 5%
non-fat milk powder (Bio-Rad Laboratories, Hercules,
CA) for one hour. Then the membrane was rinsed three
times with PBS + 0.1% Tween-20, and incubated with
the primary antibodies at 4°C overnight in PBS + 5%
BSA. pSTAT3 (Tyr705, Cat#: 9145 s) and STAT3 (Cat#:
9139 s) antibodies (Cell Signaling Technology) were
used at 1:1000 dilution.. HRP-conjugated secondary anti-
body was used at 1:10,000 dilution and incubated with
the membrane at room temperature for one hour. Signal
was visualized with Visualizer™ Western Blot Detection
Kit (Millipore, Billerica, MA) using AlphaImager™ 3400
system (Alpha Innotech) and FluorChem 5500 software
(Alpha Innotech).
pSTAT3 whole blood assay
Assay was done as previously described [17] with slight
modifications. Briefly, blood from healthy volunteers was
drawn with heparin as the anti-coagulant, and assayed
within 2 hours after blood collection. Blood was ali-
quoted into 100 ul/ well in 96 well deep well plates and
incubated at 37°C for 30 minutes with the indicated
amount of ATR-107 or control Ab (hIgG1-TM). Blood was
then treated with 1 – 1000 ng/ml of IL-21 for 15 minutes
at 37°C, followed by addition of 10 volumes of 1X lyse/fix
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anti-CD19 FITC (BD Biosciences) were added 15 minutes
before the IL-21 for surface staining for a total of
30 minutes. Samples were washed twice by centrifugation
using PBS containing 2% heat inactivated FBS, then
permeabilized with 80% ice cold methanol for 30 minutes.
Alexa Fluor 647 (A647) labeled anti-pSTAT3 (Tyr705)
antibody (BD Biosciences, cat#: 557815) was then ad-
ded and incubated at 4°C overnight. Data was collec-
ted the next day on FACS Calibur (BD Biosciences) or
LSRFortessa (BD Biosciences) and analyzed using Flowjo
software (version 7.6.1, Tree Star, Inc. Ashland, OR).
Target coverage
To understand the level of ATR-107/IL-21R binding, an
Alexa Fluor 647 dye was conjugated directly to ATR-107
(ATR-107-A647) with a dye to antibody ratio of 3:1 to 5:1.
To evaluate the competition between ATR-107-A647
(3.6 ug/ml) and IL-21, these two reagents were added to
the samples at the same time, and the reaction was
stopped after 30 minutes using 10 volumes of 1X Lyse/Fix
buffer. The remaining cells were washed twice with PBS
containing 2% heat inactivated FBS. Samples were then
subjected to data collection using FACS Calibur (BD
Biosciences) or LSRFortessa (BD Biosciences) without
fixation, permeabilization and intracellular staining. Maxi-
mum binding was determined by incubating samples with
only ATR-107-A647. Non-specific binding (NSB) was
determined by incubating samples with ATR-107-A647
in the presence of excessive amount of unconjugated
ATR-107 (363 ug/ml). Non-specific binding (NSB) was
subtracted from each data point and the resulting value
expressed as a percentage of maximum binding.
To compare the target engagement and functional ef-
fects on the signaling, the receptor occupancy assay was
done side-by-side with the pSTAT3 assay. In those ex-
periments, the receptor occupancy assay was performed
similar to the pSTAT3 assay except that A647-ATR-107
was added to the samples, instead of IL-21.
Imaging flow cytometry
To validate functional response, the translocation of
pSTAT3 to the nucleus of CD4+ T lymphocytes in response
to IL-21 was determined using an Amnis ImageStream 100
(Amnis Corporation, Seattle WA). The method to prepare
samples for imaging analysis was similar to the aforemen-
tioned pSTAT3 whole blood assay, except that the nuclear
dye DAPI (4.5 μM final concentration) was incubated with
permeabilized and stained leukocytes prior to cellular ac-
quisition by the ImageStream. The data were analyzed with
a nuclear translocation analysis wizard in the IDEAs soft-
ware (Amnis Corporation), as previously described [18].
Briefly, single focused leukocytes were identified and then
followed by gating DAPI- and A647-double positive events.Nuclear translocation of pSTAT3 in CD4+ events was mea-
sured by a nuclear morphology mask to assess a similarity
score of the correlation of pixel values between DAPI and
A647-pSTAT3 images on a per-cell basis.
Data analysis
The percent of maximum pSTAT3 was determined by
subtracting the background (autofluorescence) value
from each data point. This corrected value was then
divided by the maximum response for a given dose of
IL-21 and multiplied by 100.
Statistical analysis
Data from different donors were pooled together using
the percentage of maximum activation described above,
and the IC50 was calculated using GraphPad Prism soft-
ware version 5.02 (La Jolla, CA) using least square fit
analysis.
Results
ATR-107 inhibits IL-21 induced phosphorylation and
nuclear translocation of STAT3
Even though IL-21 activates several STAT proteins in-
cluding STAT1, STAT3, STAT5a and STAT5b, the acti-
vation of STAT3 was studies since it is the most
significant and sustained for this pathway [3]. To dem-
onstrate that ATR-107 blocks the function of IL-21,
CD4+ T cells, isolated from healthy donor peripheral
blood, were stimulated with IL-21 for 15 minutes in the
presence of various concentrations of ATR-107. Phos-
phorylation of STAT3 was visualized by Western blot-
ting using an antibody specifically against pSTAT3
(Tyr705) (Figure 1A). IL-21 strongly induced phospho-
rylation of STAT3, while it didn’t change the expression
of total STAT3. This IL-21-induced phosphorylation of
STAT3 was inhibited by ATR-107 in a concentration-
dependent manner, with maximal inhibition observed at
or above a dose of 10 ng/ml.
The activity of ATR-107 was further evaluated when
present in human blood using flow cytometry, a techno-
logy which is capable of sorting out cell populations of
interest without the need for cell isolation. Phospho-
STAT3 was measured using a specific antibody con-
jugated with fluorophore, thus allowing a quantitative
analysis. Similar to isolated CD4+ T cells, phosphoryla-
tion of STAT3 was robustly induced by 10 ng/ml IL-21
in CD4+ T cells in whole blood as quantified by the in-
tensity of the fluorescence, and ATR-107 concentration
dependently inhibited IL-21-induced phosphorylation of
STAT3 (Figure 1B). When levels of pSTAT3 (fluores-
cence intensity) were plotted against ATR-107 concen-
trations, an inhibition curve was generated indicating
50% of inhibition (IC50) at 1.45 ± 0.26 ng/ml, n = 6
Figure 1 (See legend on next page.)
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Figure 1 ATR-107 concentration-dependently inhibited IL-21 induced STAT3 phosphorylation. A: Purified T cells from healthy donor
peripheral blood were pre-incubated with ATR-107 at concentrations from 0.03 ng/ml to 100 ng/ml or control antibody for 30 minutes, followed
by stimulation with IL-21 (10 ng/ml) for an additional 15 minutes. Total and phospho–STAT3 was detected by Western blot. B: Healthy donor
whole blood was pretreated with ATR-107 or control Ab for 30 minutes prior to stimulation with 10 ng/ml IL-21 for 15 minutes. Cells were fixed,
permeabilized, stained with A647-labeled anti–phospho–STAT-3 antibody, and analyzed using flow cytometry gated on CD4+ T cells.
Representative histogram showing the baseline (gray area), IL-21 + control Ab (red line) and IL-21 with various amount of ATR-107. C: Inhibition of
ATR-107 on pSTAT3 mean fluorescence intensity (MFI) induced by 10 ng/ml IL-21(n = 6). D: Representative image of 6 individual cells detected by
ImageStream cytometer (ISC) after treatment with 10 ng/ml IL-21 for 15 minutes. In addition to the bright field image (left column), cells were
stained with CD4 (blue), DAPI (green) and pSTAT3 (red). Merged imaging shows pSTAT3 staining overlap with the nuclear (DAPI) staining (far
right column). E: Translocation of pSTAT3 was completely blocked by pre-treatment of the samples with ATR-107 (4.3 ug/mL) for 30 minutes. F:
Overlay of similarity of nuclear pixel images of DAPI and AF647 dyes in CD4+ T cells. Autoflurorescence (AutoFl) was a measurement of the
sample treated with neither ATR-107 nor IL-21. The data were analyzed by the IDEAs software (Amnis Corporation).
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cells were gated for analysis (data not shown).
Once phosphorylated, STAT3 forms dimers and translo-
cates to the nucleus. We further examined the effect of
ATR-107 on nuclear translocation of STAT3 using ima-
ging flow cytometry. Cells were interrogated individually,
fluorescence intensity recorded and images captured in
imagestream cytometry. With the help of nuclear staining,
the nucleus can be identified within the cell. As seen in
Figure 1D, after IL-21 stimulation, an increase of phospho-
STAT3 was detected (in red). Phospho-STAT3 was located
in the same cellular compartment as the nuclear staining
(in green). Merging of these two images (right column)
confirms they overlap with each other. Pretreatment of
cells with ATR-107 blocked phosphorylation of STAT3
and prevented STAT3 from translocating to the nucleus
(Figure 1E) as no overlap of phospho-STAT3 and the
nucleus was detected. Consistent with the images seen
with individual cells, the nuclear translocation response to
IL-21 in CD4+ cellular population, as shown in Figure 1F,
was markedly increased and was exquisitely sensitive to
ATR-107 pre-incubation. Collectively, these data shows
ATR-107 blocks not only IL-21 induced STAT3 phospho-
rylation, but nuclear translocation in human CD4+ T cells.
ATR-107 behaves like a non-competitive inhibitor for
IL-21 signaling
To characterize the inhibitory activity of ATR-107, inhi-
bition curves for this molecule were generated using dif-
ferent amounts of IL-21. Pooled data from 4–6 donors
showed that 15 minute incubation with increasing
amounts (1 – 100 ng/ml ) of IL-21 led to a proportional
increase in the levels of STAT3 phosphorylation in CD4+
T cells (Figure 2A). Maximal effect was found when cells
were treated with 100 ng/ml of IL-21, since similar levels
of pSTAT3 were observed with a dose of 1,000 ng/ml of
IL-21. ATR-107 concentration-dependently inhibited the
STAT3 phosphorylation at all doses of IL-21. However,
the inhibition curves did not shift to the right in a parallel
manner with increasing concentrations of IL-21. Further-
more, ATR-107 at the dose of 10 ng/ml almost completelyblocked STAT3 phosphorylation, regardless of the IL-21
concentration that was used for stimulation (Figure 2A).
These data suggest that ATR-107 is not functioning as a
typical competitive inhibitor of IL-21. Similar results were
observed when data was analyzed in CD19+ B cells
(Figure 2B).
To better observe the mechanism of inhibition, the same
data were re-plotted to show the IL-21 dose response
curve, in the presence of different amounts of ATR-107
(Figure 2, C and D). Consistent with data shown in
Figure 2A and B, IL-21 increased pSTAT3 level concentra-
tion dependently. However, when the ATR-107 concentra-
tion is higher than 0.64 ng/ml, the maximum stimulation
could not be reached by 100 ng/ml or 1000 ng/ml of
IL-21. This suggests the blockade of ATR-107 could not
be overcome by high doses of IL-21, and indicates the
non-competitive nature of this antibody.
ATR-107 competes with IL-21 for receptor occupancy
To further characterize its mechanism of action, an
IL-21R occupancy assay was developed [19]. For this pur-
pose, ATR-107 was labeled with A647 and its binding to
the IL-21R was tested in the presence of different amounts
of IL-21. For this experiment, naïve B cells were chosen
since they have high amounts of IL-21R (data not shown).
Also, ATR-107-A647 was not pre-incubated with the sam-
ples. In other words, IL-21 and ATR-107-A647 were
added at the same time to determine their initial rate of
competitive binding (kon). As expected, the binding of
ATR-107-A647 to naïve B cells decreased with increasing
amounts of IL-21 with an IC50 of 21.6 nM (Figure 3).
Similar results were observed using a commercially avail-
able IL-21 (eBioscience, San Diego, CA) (IC50 of 53 ±
23 nM, n = 3). This data suggest ATR-107 does compete
with IL-21 for receptor binding when they were both
added at the same time, regardless of the IL-21 source.
Inhibition of ATR-107 on IL-21 induced pSTAT3 correlates
with its receptor occupancy
To further validate this assay, and to understand if the
ATR-107 blockade measured by the functional pSTAT3
Figure 2 ATR-107 behaves like a non-competitive antibody. Summarized results of ATR-107 inhibition on STAT3 phosphorylation in
peripheral T (A) and B (B) cells induced by different amount of IL-21. Whole blood was pre-incubated with various amounts of ATR-107, as
indicated on the graphs, for 30 minutes, followed by 1–1,000 ng/ml of IL-21 stimulation for 15 minutes. The reaction was stopped, and the RBC
removed by adding the BD Lyse/fix buffer. The remaining cells were then washed, permeabilized and stained for pSTAT3. Shown are the means ± SE
from 2–3 separate experiments. % of Max was defined as: (MFI – background) / (Max response – background) X 100. Same data was
re-plotted with IL-21 at the x-axis (C, D).
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assays were performed side by side in several different
experiments. For this experiment, ATR-107 was pre-
incubated for 30 minutes, and then either A647-labeled
ATR-107 or IL-21 was added to assess the level of IL-21
receptor occupancy and STAT3 phsophorylation. As
seen in Figure 4A for T cells and Figure 4B for B cells,
an excellent inverse correlation was observed between
the inhibition of the pSTAT3 signal and the occupancy
of the IL21R by ATR-107. The receptor occupancy assay
was then used to analyze blood samples obtained from
healthy volunteers treated with a single dose of 60 mg of
ATR-107. Complete receptor occupancy was observed
for up to 42 days post-dose as reported by Pleasic-
Williams et al. [19]. At the same time, the pSTAT3 res-
ponse was determined by adding a dose of 10 ng/ml of
IL-21 to the healthy volunteer blood. The pSTAT3 res-
ponse in CD4+ T cells was inhibited by more than 90%
in all treated subjects (n = 4) as compared to the signalgenerated in the placebo group (n = 3). This indicates
again that these two assays correlate well with each
other, and ATR-107 has a long pharmacodynamic effect
in vivo [19].
Discussion
One of the important strategies to understand the
pharmacology of a new drug candidate is the use of bio-
markers that can provide pharmacodynamic information
from clinical samples regarding the interaction of the
drug with its target. The effects of ATR-107, an antibody
against the IL-21R, in suppressing IL-21 effects on im-
mune cells were analyzed by measuring the effects of
this antibody on the activation of STAT3. Other γc cyto-
kines, such as IL-2, IL-7, and IL-15, predominantly
phosphorylate STAT5 upon stimulation, while IL-21 pre-
dominantly phosphorylates STAT3. Additionally, STAT3
has a prolonged activation over other STATs and plays a
critical role in the IL-21 signaling [3]. pSTAT3 mea-
Figure 3 ATR-107 competes with IL-21 for receptor binding on naïve B-cells (CD19+CD27-). A: Increasing concentrations of IL-21 decreased
binding of ATR-107-A647 to the naïve B-cells as measured by the A647 fluorescence using flow cytometry. Maximum binding was determined by
incubating human blood with ATR-107-A647 (3.6 ug/mL) in the absence of IL-21. Non-specific binding (NSB) was subtracted from each data point
and the resulting value expressed as a percentage of maximum binding. B: Representative flow cytometry histograms showing the overlay of the
receptor occupancy performed without (blue line), or with either excessive concentration of IL-21 (707 nM, red line) or ATR-107 (363 ug/ml, black
line). At least 2000 CD19+CD27-events were acquired for analysis.
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flow cytometry analysis allowing the generation of excel-
lent dose response curves and a good IC50 determinaion.
Thus, phospho-STAT3 was selected as a biomarker for
IL-21. Using Western blot, we clearly demonstrated the
phosphorylation of STAT3 by IL-21 in T cells. The spe-
cificity of the pSTAT3 signal and, the inhibitory effects
of ATR-107, were demonstrated by the concentration-
dependent inhibition of pSTAT3 using Western Blot. To
further our analysis into specific cell types, flow cytome-
try was used. Phospho-specific flow cytometry measures
the phosphorylation state of the interested kinase(s) at a
single cell level in a heterogeneous cell population [20].
Since the specific cell type can be identified by theFigure 4 ATR-107 inhibition on IL-21 induced STAT3 phosphorylation
Receptor occupancy assays and pSTAT3 assays were performed side by sid
incubated with ATR-107 for 15 minutes at 37°C, and stained with cell surfa
10 ng/ml of IL-21 were added to the wells, and incubated at 37°C for anot
occupancy assay), followed by the addition of the Lyse/fix buffer to stop th
were washed twice with PBS + 2% FBS. Samples were then collected with
permeabilization and stained with pSTAT3 A647. Data shown are the meansimultaneous surface staining, there is no need to isolate
the cells of interest. Another advantage is that the cells
are kept in the whole blood environment during stimula-
tion enabling the measurements in a more physiological
condition.
Using flow cytometry analysis, pSTAT3 was detected
in CD4+ T and CD19+ B cells. STAT3 signal transduc-
tion pathway is well known. After activation by phos-
phorylation, pSTAT3 translocates to the nucleus and
transcription is initiated [3]. Indeed, when IL-21 was
added to whole blood, a concentration- and time-
dependent increase in pSTAT3 signal was observed that
coincided with the movement of the transcription factor
to the cell nucleus. This was clearly visualized usingcorrelates inversely with IL-21R occupancy, ex vivo (A, B).
e in T cells (A) and B cells (B). Briefly, whole blood samples were pre-
ce markers (CD4, CD19) for 15 minutes. Then either ATR-107-A647 or
her 15 minutes (for pSTAT3 assay) or 20 minutes (for receptor
e reaction and to remove RBC. After centrifugation, the cell pellets
(for pSTAT3 assay) or without (for receptor occupancy assay)
s ± SE from 8 donors.
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of ATR-107, no pSTAT3 signal was observed in the nu-
cleus by looking at the cells using ImageStream, agreeing
with the lack of nuclear translocation.
Interestingly, ATR-107 inhibited the signal and the
mechanism of inhibition was shown to be non-
competitive. This mechanism of inhibition was demon-
strated in both T and B cells. The data suggest that
ATR-107 binding to the IL-21R is initially competitive
with IL-21. However, once the antibody binds to the re-
ceptor, IL-21 cannot displace it from the receptor, thus,
ATR-107 behaves like a functional non-competitive
agent. This phenomenon is likely due to the long koff
(2.91 x 104/s, t1/2: 39 min) of this antibody [14] which
generates slow-reversible binding, an inhibitory feature
of ATR-107. The non-competitive nature of inhibition
demonstrated by ATR-107 may have important pharma-
cological consequences, since this mechanism could pro-
duce pharmacodynamic effects much longer that what is
expected based on the pharmacokinetic characteristic of
the molecule. Indeed, initial clinical data is suggestive of
this effect where full receptor occupancy was observed
for at least 42 days after a single administration of ATR-
107 [19], an effect that was also demonstrated using
pSTAT3 as a pharmacodynamic biomarker. These re-
sults in humans confirmed the previous observation of a
5–13 week pharmacodynamic efficacy observed in non-
human primates using the IL-2R transcript as a PD bio-
marker [15].
Another important piece of information obtained from
this study is that it is feasible to consider that the anti-
body binds the receptor initially in the cells that are cir-
culating in the blood compartment and these cells may
either not be able to infiltrate to the inflamed site or if
they do, they may help transport the antibody to the
inflamed tissues increasing its concentration at the site
where it is needed. These possibilities will need to
be demonstrated in further studies. Recent studies
(Palandra et al. submitted Analytical Chemistry 2013)
using a very specific mass spectrometric method to de-
tect and quantify IL-21 demonstrated that IL-21 is not
present in the circulation and rather is detected in in-
flamed tissues. This observation suggests that the anti-
body needs to inhibit the IL-21R at the inflamed site to
be effective.
In summary, the results reported have two clinical ap-
plications. First, the functional pSTAT3 assay correlates
well with the IL-21 receptor occupancy, suggesting these
two assays could be used to support each other in
assessing the pharmacology of ATR-107 in patients.
Second, the pSTAT3 assay helped to discover the non-
competitive feature of ATR-107, which provides impor-
tant new information to predict ATR-107 effective dose
selection. The data shows ATR-107 can completelyblock IL-21 induced STAT3 phosphorylation, regardless
of the IL-21 concentration. Thus, for therapeutic pur-
poses, the amount of IL-21R present on the cells at the
inflamed site, but not the IL-21 levels is key to
predicting the ATR-107 dose.
An important caveat from our studies is that all the as-
says reported here were done using blood from healthy
donors. Levels of IL-21 and IL-21R could be quite differ-
ent in patients with autoimmune diseases. For example,
in lupus, the IL-21 producing T cells have been shown
to be increased [21,22], while the IL-21R expression on
B cells appears to be decreased [23] or unchanged [24].
Also, there may be changes in the sensitivity of the re-
ceptor activation as has been suggested for IL-21 in B
cells in systemic lupus [24]. Thus, it is conceivable that
the responses of immune cells to IL-21 and to ATR-107
blockade could be different in patients than in healthy
controls. Thus, to accurately choose the therapeutic
doses, the assay will need to be validated using blood
from patients with the specific disease being targeted.
Conclusions
Overall, this study shows that pSTAT3 can be used as a
target biomarker to understand the inhibitory properties
of ATR-107 in humans and it may help with the transla-
tion of preclinical information and dose selection to-
wards ATR-107 clinical efficacy.
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